Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines - Wikidata - wikimedia - TriplyDB

Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines

Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines

http://www.wikidata.org/entity/Q39973753

about

The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints Targeting Epigenetic Processes in Photodynamic Therapy-Induced Anticancer Immunity Customized targeted therapy in Hodgkin lymphoma: hype or hope?Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy Pediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine.Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance.The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.EBV-positive Hodgkin lymphoma is associated with suppression of p21cip1/waf1 and a worse prognosis.Histone deacetylase inhibitors in Hodgkin lymphoma.Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.Recent Advances in the Pathobiology of Hodgkin's Lymphoma: Potential Impact on Diagnostic, Predictive, and Therapeutic Strategies.The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML.Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib.The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma.Classical Hodgkin's lymphoma shows epigenetic features of abortive plasma cell differentiation.The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines.STAT6 activation in ulcerative colitis: a new target for prevention of IL-13-induced colon epithelial cell dysfunction The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma.Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo.Regulation of immune responses by histone deacetylase inhibitors The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines.Trial watch: Chemotherapy with immunogenic cell death inducers CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma.Chemokine CCL17 induced by hypoxia promotes the proliferation of cervical cancer cell.A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517.Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment Relapsed Hodgkin lymphoma: management strategies Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy.Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.IL-13/STAT6 signaling plays a critical role in the epithelial-mesenchymal transition of colorectal cancer cells.Emerging drugs for Hodgkin's lymphoma.Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas.Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma.

P2860

Q26745842-17EDE958-FABF-40A6-86A9-DDA72C3FEB7F Q26797280-D433A717-D3E4-41D2-B655-2E94C6AB29A7 Q27002554-9564E0DA-782C-4E4F-9971-B58163B1F61D Q28082536-27DF23A3-10EA-4919-B4AE-B62E1D0104FA Q30248284-21CE9C1C-4301-43C8-B8E0-BA7556F89330 Q30251920-0A6E8137-9213-40AE-AA8E-4B9459F49373 Q33392081-633D5E57-67E6-4D5D-9FF1-FD3D3DFC648A Q33410761-234C85B6-175F-47C5-BFEE-0FD449568955 Q33432027-2C36E641-0FAC-4427-B6E5-8F544B87D154 Q33711558-DB44203C-BAF5-4A3F-A534-2EFA97D8CEB1 Q34414440-77525E2F-3525-49E1-B1F5-B2B062305C03 Q34414452-4C080326-26FB-43FD-B201-1D96ACB8678E Q34557179-3E9872B8-3301-45E0-87DC-0531E636D204 Q34640790-844C72D4-6A2A-45AE-B166-AF5D586DB07E Q34648812-F78E5B52-2A6F-44B7-B8B3-0D9CC6D17D2C Q34672100-72A5B56B-0FFD-458B-AB29-984D19EC8026 Q34707183-41123040-B6CB-4C66-8632-3C43A89D2273 Q35018530-46EC4FDC-0624-4BC6-8290-603B60611758 Q35053177-153822C9-7C70-4394-B303-15E311D6C40A Q35061825-0FF72EBF-F0E0-4C67-929F-8C28985FD6C5 Q35223868-CCDF9BCD-6A06-4EA4-BB1C-F27E856BE7FD Q35235267-70E047BF-1D6C-4959-9765-70A0EA1AF01E Q35664956-3190E041-C994-42A9-90CA-60ACC313DD04 Q35741591-0E5800ED-0BD3-4580-93DC-00DD11BEB6F9 Q35855571-71FD451B-AD5A-4FFF-AAB9-195CC4F04944 Q35953399-D01104F9-79A0-4C66-947D-684CAFEFC945 Q36038456-1ECA06F1-2430-452F-879D-F4C972FE6D08 Q36288217-B111DF76-2956-4ADE-8084-8982F9FB86A6 Q36309396-CB3BB7FF-B1D4-4022-B7A0-00AD8C03256A Q36337623-D8691411-F658-48FE-9702-BAFDF13AB6B4 Q36660672-A9F1E606-2E02-48CC-973B-EBBA1A9E858A Q36922528-37BA6304-7348-40F0-AAAC-49DE56D079C3 Q37008427-4481F3AB-B957-404B-BC8A-5521F6E50529 Q37296330-F0AC9C50-668C-4EFF-8CA2-E99E08696582 Q37417291-1FFB48D5-583F-4038-A051-674A44C981D3 Q37421431-D3255B0C-07FE-4310-AEB9-3F6F8B122AA3 Q37641580-EA88800B-BEE8-4A72-9996-BA81EAC9DB1E Q37772513-389FF111-4838-4219-AA13-72E2F10D93E5 Q37774667-8E7C090A-745C-4526-8CEC-F88D0720764E Q37786716-6EDFA7F1-DAF5-4F01-BF15-FC4CA6849A66

P2860

Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines

http://www.wikidata.org/entity/Q39973753

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Vorinostat inhibits STAT6-medi ...... in Hodgkin lymphoma cell lines

@en

Vorinostat inhibits STAT6-medi ...... n Hodgkin lymphoma cell lines.

@nl

type

label

Vorinostat inhibits STAT6-medi ...... in Hodgkin lymphoma cell lines

@en

Vorinostat inhibits STAT6-medi ...... n Hodgkin lymphoma cell lines.

@nl

prefLabel

Vorinostat inhibits STAT6-medi ...... in Hodgkin lymphoma cell lines

@en

Vorinostat inhibits STAT6-medi ...... n Hodgkin lymphoma cell lines.

@nl

P1433

Q39973753-295553B7-DD9C-425B-95F6-0CE9D425EFF3

P1476

Q39973753-A7644F96-E0CD-4906-B3CB-4BD5926C8F96

P2093

Q39973753-07935A3D-8C69-44F8-96BD-EBCA7DED643B

Q39973753-275EBB7B-A12B-436F-822F-BD2771E609D4

Q39973753-681B3EB7-3D27-4913-B73A-8EE1FF69F9D0

Q39973753-718F8339-B9C2-48A8-A313-9FF0DD3F0036

Q39973753-946B98B0-6A30-41B4-903A-015EBAA0A470

Q39973753-EE81D9B6-DC85-497A-9676-1E30987BBCEB

P2860

Q39973753-0B11F45F-DC02-4AE5-8BC0-DEA21F34411E

Q39973753-0D90495F-5207-4D68-A722-FEC474A34298

Q39973753-0E9C9E26-E8F9-4D1C-896B-0CD78F266A1F

Q39973753-13AF5E70-3D0D-434B-8B43-67BD172477FA

Q39973753-28120AF9-7B4D-43BD-9CD0-1FB749EC81BA

Q39973753-2A8B2AE7-41E1-4170-B44F-9EF9A7EEC155

Q39973753-2A924020-D1CC-4C41-948B-CA09495F165F

Q39973753-2D8D821B-52E2-4A4F-BACA-018AB4E85BDA

Q39973753-35D4BCAC-1AA0-4DE0-9E9B-A9B78F0C600E

Q39973753-3A1F5F6F-8793-4BBC-9D32-AA61739C05E1

P304

Q39973753-87D56499-FB3D-424A-A7B1-E2CBA10ADB2C

P31

Q39973753-26D904D2-F05C-4A35-8681-63DED7E35885

P356

Q39973753-EF095B6A-6832-482D-B3DD-3B2AAA5EA37D

P407

Q39973753-39EF8175-86C5-4910-864C-D6935CA3A78C

P433

Q39973753-E677981F-291F-4C77-A5D7-01A5B7DE2C5D

P478

Q39973753-85325D82-41B9-4FED-B42D-1A64DD9AA984

P50

Q39973753-08614BA6-4F06-4832-B82E-8219D1C04741

P577

Q39973753-784316FE-D0D5-465B-A1F0-4DEBFD051F3C

P5875

Q39973753-D3E44111-5988-416A-B37E-4E64D437BA1A

P698

Q39973753-AF6EF98F-FD31-47AC-ADBA-029480BCEFD0

P932

Q39973753-24477C78-C829-4056-9499-7114F1DD079B

P356

BLOOD-2008-01-133769

P1433

P1476

Vorinostat inhibits STAT6-medi ...... in Hodgkin lymphoma cell lines

@en

P2093

Anas Younes

http://www.w3.org/2001/XMLSchema#string

Daniela Buglio

http://www.w3.org/2001/XMLSchema#string

Georgios V Georgakis

http://www.w3.org/2001/XMLSchema#string

Noor M Khaskhely

http://www.w3.org/2001/XMLSchema#string

Shino Hanabuchi

http://www.w3.org/2001/XMLSchema#string

Yong-Jun Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

Interleukin-4 induction of the CC chemokine TARC (CCL17) in murine macrophages is mediated by multiple STAT6 sites in the TARC gene promoter.

Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.

Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation.

Signaling mechanisms, interaction partners, and target genes of STAT6.

Apoptotic and autophagic cell death induced by histone deacetylase inhibitors.

Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP.

Stat3 dimerization regulated by reversible acetylation of a single lysine residue.

P304

1424-1433

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2008-01-133769

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5315140

http://www.w3.org/2001/XMLSchema#string

P698

18541724

http://www.w3.org/2001/XMLSchema#string

P932

2515130

http://www.w3.org/2001/XMLSchema#string